This measure assesses the percentage of members 18–64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening during the measurement year.
Why It Matters
People with schizophrenia, schizoaffective disorder or bipolar disorder are at greater risk of metabolic syndrome due to their serious mental illness.1 Diabetes screening is important for anyone with schizophrenia, schizoaffective disorder or bipolar disorder, and the added risk associated with antipsychotic medications contributes to the need to screen for diabetes. Diabetes screening for individuals with schizophrenia, schizoaffective disorder or bipolar disorder prescribed an antipsychotic medication may lead to earlier identification and treatment of diabetes in these groups.
Historical Results – National Averages
Get Access to the Historical Results
By completing the form below, you’ll gain free access to national performance data.
"*" indicates required fields
References
- Vancampfort, D., B. Stubbs, A.J. Mitchell, M. De Hert, M. Wampers, P.B. Ward, S. Rosenbaum, and C.U. Correll. 2015. “Risk of Metabolic Syndrome and Its Components in People with Schizophrenia and Related Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review and Meta-Analysis.” World Psychiatry 14 (3): 339–47.
- Save
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
- Email
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
- Print
Print this page.
Print this page.